Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
ARS Pharmaceuticals (SPRY) Stock Price & Analysis
198 Followers
SPRY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.55 - $11.27
Previous Close$9.24
Volume477.15K
Average Volume (3M)675.91K
Market Cap
$891.67M
Enterprise Value$663.59M
Total Cash (Recent Filing)$228.36M
Total Debt (Recent Filing)$274.00K
Price to Earnings (P/E)-16.2
Beta0.94
Next Earnings
May 13, 2024EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding96,501,554
10 Day Avg. Volume540,004
30 Day Avg. Volume675,913
Standard Deviation0.21
R-Squared0.04
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.77
Price to Sales (P/S)29722.48
Price to Cash Flow (P/CF)-12.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.12K
Enterprise Value/Gross Profit22.12K
Enterprise Value/Ebitda-14.82
Forecast
1Y Price Target
$19.00Price Target Upside106.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ARS Pharmaceuticals News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $2.55 and its highest was $11.27 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
Currently, no data Available
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is May 13, 2024 which is in 25 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Mar 21, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.137 by $0.067.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -$0.1.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 96,501,560 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.137. Following the earnings report the stock price went down -3.889%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Among the largest hedge funds holding ARS Pharmaceuticals’s share is Deerfield Management Company, LP. It holds ARS Pharmaceuticals’s shares valued at 61M.
---
ARS Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (106.97% Upside)
$19.00 (106.97% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 175.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Company Description
ARS Pharmaceuticals
Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.
---
SPRY Stock 12 Months Forecast
Average Price Target
$19.00
▲(106.97% Upside)
Technical Analysis
Best Analysts Covering SPRY
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+58.08%
assigned a buy rating last month
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +58.08% per trade.
---